Neurizon Therapeutics Reports Promising Results from NUZ-001 ALS Study

Pharmaust Limited ( (AU:NUZ) ) has issued an announcement.

Neurizon Therapeutics Limited announced the successful completion of a 12-month Open Label Extension (OLE) study for its drug NUZ-001, which has shown promising results in extending the life expectancy of ALS patients. The study revealed that NUZ-001 significantly increased survival rates and reduced the risk of death by 78.5% compared to untreated controls, with no serious adverse events reported. These findings underscore the potential of NUZ-001 to provide meaningful clinical benefits, potentially extending life expectancy by approximately 11 months, which is notably longer than existing treatments.

More about Pharmaust Limited

Neurizon Therapeutics Limited is a clinical-stage biotech company focused on developing innovative treatments for neurodegenerative diseases, particularly amyotrophic lateral sclerosis (ALS).

YTD Price Performance: -21.98%

Average Trading Volume: 31,142

Technical Sentiment Signal: Buy

Current Market Cap: €39.31M

Learn more about NUZ stock on TipRanks’ Stock Analysis page.